Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
As several of the big 11 pharma companies dialled back on acquisitions, the collective bill for M&A and R&D activities among this cohort took a dip for the second consecutive year in 2022, even as Pfizer marched on with its spending spree. Their collective expenditure – $157 billion – might be the smallest since 2018, but it's still a…
There are some things in life you want to be consistent and predictable. Interest rates. Train timetables. The weather. And if you work in the pharma industry, the…
What happened in Q3? Did the glimmers of light we saw at the start of the quarter really come to anything or were they a false dawn? In this eBook, we investigate whether…
In this quarterly snapshot, we highlight financial and business trends in biopharma. Download our Q3 Roundup infographic now for our quick take on M&A activity, the…
Commercial analytics and forecasting underpin strategic decision-making and business planning across the pharmaceutical and life science sectors. Inaccurate risk…
Digital technologies have plenty to offer a pharma industry seeking to up its productivity game. Attention often focuses artificial intelligence powered drug discovery or…
After a 27-month rollercoaster ride, can we expect a return to normal? Battered biotech is reviving after booming and busting in spectacular fashion. M&A is…
Our annual World Preview infographic provides forward-looking analysis of the pharma and biotech market, based on Evaluate consensus forecasts to 2028. The top…
The European Society of Medical Oncology Conference (ESMO) in Paris has wrapped up and there was much to talk about as Europe’s top oncologists came together to announce…
Amid the challenges of a global pandemic, parts of the medtech sector were positioned to reap some of the spoils enjoyed by the big pharma players. Huge demand for Covid…
Amid the challenges of a global pandemic, parts of the medtech sector were positioned to reap some of the spoils enjoyed by the big pharma players. As the pandemic…